Coastal Infusion Administers Omvoh™
| J-Code | J2267 |
|---|---|
| Manufacturer | Lilly |
| First Approved | 10/26/2023 |
Coastal Infusion can administer your Omvoh prescription at any of our south Florida locations.
Omvoh (mirikizumab-mrkz) is an interleukin-23 antagonist indicated for the treatment of moderate to severe ulcerative colitis. Omvoh is used to treat moderate to severe UC when conventional therapy or biological treatments have stopped working, or cause unacceptable side effects
The active substance in Omvoh, mirikizumab, is an antibody designed to attach to interleukin-23 (IL-23) and block its activity. IL-23 is a protein that controls the growth and maturation of some types of T cells. These T cells are involved in causing inflammation that is linked to the development of ulcerative colitis. By blocking the action of IL-23, Omvoh reduces inflammation and symptoms associated with the disease.
What It Treats
Omvoh is used to treat Moderate to severe Ulcerative Colitis (UC).
Prescribed By
Omvoh is most often prescribed by Gastroenterologists.
How it’s Administered
Omvoh is administered by subcutaneous injection. Omvoh injections take only a few minutes.
Frequency
Omvoh is generally administered three times over eight weeks.
Related Drugs
Additional Resources
The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies